IncellDx

IncellDx is a precision medicine company that develops diagnostics and prognostics to better understand and treat cancer and infectious diseases. The company and its CEO, Bruce Patterson, have made news for IncellDx’s timely focus on improving the characterization and targeted treatment of chronic COVID through the identification of specific biomarkers and symptoms. In 2023, when Patterson announced that the California-based company would transfer some of its operations to the Traverse City area, Boomerang Catapult became a lead Traverse City IncellDx investor.